Showing just a few of what will be discussed:
| Teva to present Laquinimod data at Hawaii conference Globes Online Thu, 07 Apr 2011 09:21 AM PDT The Phase III trial of the oral multiple sclerosis drug showed a statistically significant reduction in annualized relapse rate and in the disability progression. |
|
Press Release
PharmiWeb Thu, 07 Apr 2011 08:04 AM PDT Genzyme , a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology’s (AAN) 63rd Annual Meeting in Hawaii, April 9 – 16, 2011. Included among the additional Phase 2 trial safety and efficacy data at AAN … |
|
Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology
Business Wire Thu, 07 Apr 2011 06:21 AM PDT CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genzyme, a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology’s (AAN) 63rd Annual Meeting in Hawaii, April 9 – 16, 2011. Included among the additional Phase 2 trial … |
EMD Serono Inc. Posted on:08 Apr 11 EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company‘s multiple sclerosis (MS) portfolio will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) taking place from April 9 to 16, in Honolulu, Hawaii.
****************************************************************
Remain CURRENT with Multiple Sclerosis information
when registered at the MS Views and News website
.
***************************************************************************************
.
“Providing You with ‘MS Views and News’, is what we do“
***************************************************************************************
.
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews